Ann: Latest Patient Group Show Best Results to Date at 30 Days, page-104

First 104 Last

Share
Profile

Follow
thewood

186 Posts.

88

28/06/23

15:58

Post #: 68516740
Share

Originally posted by Eire2011 ↑

I understand your point fully and you may be right. However, everything has changed and not in a way the FDA expected and so something needs to be done.

We now have the first batch of younger patients from the 2019 TAVR approval for lower risk patients coming through and requiring VIV. The current solutions for VIV (for these younger patients) are no longer satisfactory. I am sure the FDA realises this. These patients are potentially going to die and the current solutions are almost palliative.

Therefore, in my view due to an unforeseen issue (created by the FDA) something has to change.

I also think that some more weight should be given to the fact that the tissue in our valve is already FDA approved and in > 50k patients globally with > 10 years anti calcification success (also in paediatrics - harder to do due to fast growth)

Our valve has also now been successfully in humans for over 3 years since the first SAVR trial in March 2023 (and 21 TAVR patients) and the mechanics of the actual device is well known to the FDA.

So if I was a betting man I would suspect that with 10 successful VIV implantations as part of an EFS may result in some negotiation regarding an earlier path to market for DurAVR as a solution to the very serious and growing issue of failed valves needing VIV.

Of course I could be wrong but this is just my own speculation.

DOYR and Not advice.

Expand

I would also point out that the DurAVR VIV that have been done have a superior results to the initial competitor valve replacement

AVR Price at posting: $21.10 Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

PAR

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

NEU

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NMT

Neometals-MinRes JV inks MOU with Rio Tinto on lithium electrolysis

First 104 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $6.00		Change -0.120(1.96%)		Mkt cap ! $94.23M

Open	High	Low	Value	Volume
$6.01	$6.08	$6.00	$20.70K	3.447K

Buyers (Bids)

No.	Vol.	Price($)
2	878	$5.86

Sellers (Offers)

Price($)	Vol.	No.
$6.00	1974	2

View Market Depth

No.	Vol.	Price($)
1	307	6.000
2	878	5.860
1	25	5.850
1	857	5.830
1	900	5.780

Price($)	Vol.	No.
6.080	260	1
6.150	2710	2
6.180	50	1
6.200	1000	1
6.400	130	1

Last trade - 12.33pm 26/06/2025 (20 minute delay)

AVR (ASX) Chart

Ann: Latest Patient Group Show Best Results to Date at 30 Days, page-104

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Neometals-MinRes JV inks MOU with Rio Tinto on lithium electrolysis

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Latest Patient Group Show Best Results to Date at 30 Days, page-104

Top Stories

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Neometals-MinRes JV inks MOU with Rio Tinto on lithium electrolysis

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News